Alzecure: Receives Approval to Start ACD856 Phase I “MAD” Study

Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Alzecure: Receives Approval to Start ACD856 Phase I “MAD” Study

FT

Fredrik Thor

AlzeCure Pharma

4.43

▲ 0.07

1.61%

Premium Plan required to unlock

We give a brief comment on today's news that Alzecure has recieved approval to start the "MAD"-part of its phase 1 study for ACD856.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

AlzeCure Pharma

4.43

▲ 0.07

1.61%

Premium Plan required to unlock